No matter how the market flourishes or how promising a technology’s outlook, there’s still one thing that can bring even the most high-flying genomics execs to their knees. It’s the US FDA, headed up by Bernard Schwetz, acting principal deputy commissioner. His years of toxicology research experience have prepared him for what may be the coming onslaught of genomics-based drugs. He recently agreed to an e-mail interview with GT’s Meredith Salisbury.